ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02263885
• Other study ID #: PD002
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: July 26, 2019

Study information

• Verified date: December 2021
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's disease (PD).

Description:

The purpose of this study is to evaluate the safety and initial clinical effectiveness of ExAblate Transcranial unilateral thermal ablation of the globus pallidus of subjects suffering from medication-refractory, advanced idiopathic PD.

Data will be collected to establish the basic safety and clinical efficacy of this type of treatment as the basis for later studies that will evaluate the full clinical efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 26, 2019
• Est. primary completion date: May 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Men and women, age 30 years and older

• Subjects who are able and willing to give informed consent and able to attend all study visits through 24 Months

• Subjects with a diagnosis of idiopathic PD

• Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.

• Disabling motor complications of PD on optimum medical treatment

• Predominant disability from one side of the body (i.e unilateral or markedly asymmetric disease) as determined by movement disorders neurologist and neurosurgeon

• Subjects should be on a stable dose of all PD medications for 30 days prior to study entry.

• Subject is able to communicate sensations during the ExAblate Transcranial procedure.

Exclusion Criteria:

• Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.

• Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.

• Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia

• Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist

• Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist.

• Legal incapacity or limited legal capacity as determined by the neuropsychologist

• Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse

• Subjects with unstable cardiac status including:

1. Unstable angina pectoris on medication

2. Subjects with documented myocardial infarction within six months of protocol entry

3. Significant congestive heart failure defined with ejection fraction < 40

4. Subjects with unstable ventricular arrhythmias

5. Subjects with atrial arrhythmias that are not rate-controlled

• Severe hypertension (diastolic BP > 100 on medication)

• Current medical condition resulting in abnormal bleeding and/or coagulopathy

• Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure

• Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution's laboratory standard

• Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis;

• Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

• Significant claustrophobia that cannot be managed with mild medication.

• Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.

• History of intracranial hemorrhage

• History of multiple strokes, or a stroke within past 6 months

• Subjects with a history of seizures within the past year

• Subjects with brain tumors

• Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.

• Are participating or have participated in another clinical trial in the last 30 days

• Any illness that in the investigator's opinion preclude participation in this study.

• Subjects unable to communicate with the investigator and staff.

• Pregnancy or lactation.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• ExAblate Transcranial System
Transcranial MRgFUS

Locations

Country	Name	City	State
United States	University of Maryland Medical System	Baltimore	Maryland
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	University of Virginia	Charlottesville	Virginia
United States	The Ohio State Wexner Medical Center	Columbus	Ohio
United States	Stanford University Medical Center	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	The primary outcome of this feasibility trial was safety. Adverse Events were categorized by physicians as mild, moderate, or severe. Events resulting in impairment, requiring intervention to preclude impairment, or that were life threatening, and deaths were reported by physicians as Serious Adverse Events. Outcomes are entered in the adverse events module.	Month 24
Secondary	Unified Dyskinesia Rating Scale Total Score.	The Unified Dyskinesia Rating Scale Total score assesses overall involuntary movements associated with the treatment of Parkinson's disease. The minimum score possible is 0. The maximum total score possible is 104. High scores show worse symptoms.	Screening, Month 3, Month 6, Month 12, Month 24
Secondary	Unified Dyskinesia Rating Scale (UDysRS), Part III	The Unified Dyskinesia Ratient Scale (UDysRS) was developed to assess involuntary movements often associated with the treatment of Parkinson's disease. Part III evaluates the intensity of impairment of dyskinesia with respect to the performance of 7 tasks on a scale of 0 to 4. The sum of the Part III score ranges 0 to 28 and high scores show worse symptoms.	Screening, Month 3, Month 6, Month 12, Month 24
Secondary	Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III Motor Exam	The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRSP Part III motor exam focuses specifically on the treated side tremor and motor fluctuations. Each of 11 items are scored from 0 to 4 for a total score minimum of 0 and a maximum of 44 points. High scores show worse symptoms.	Screening, Month 3, Month 6, Month 12, Month 24
Secondary	Mood Disorders Society - Unified Parkinson's Disease Rating Scale Part II	.Part II of the Mood Disorders Society Unified Parkinson's Disease Rating Scale focuses on the impact of symptoms on motor aspects of daily living. Part II consists of 13 items scored from 0 to 4 for a maximum score of 52. High Part II scores indicate worse (greater) impact.	Screening, Month 3, Month 6, Month 12, Month 24
Secondary	Mood Disorder Society Unified Parkinson's Disease Rating Scale Part IV	Part IV of the Mood Disorder Society Unified Parkinson's Disease Rating Scale assesses dyskinesias that include OFF-state dystonia; items include time spent with dyskinesia, functional impact of dyskinesia, time spent in the OFF state, functional impact of fluctuations, complexity of motor fluctuations and painful OFF state dystonia. Six items are scored 0 to 4 with a maximum total score of 24. High scores indicate worse symptoms.	Screening, Month 3, Month 6, Month 12, Month 24